A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma

WITHDRAWN

Identifier: CI-TRIAL-00075222
Entity page: /trial/NCT05711628 ↗
Edges: 11

Neighbours: 1 cancers9 drugs
Drawn: 10 of 10 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma condition of …CONDITION_OFderived2 of 2
← condition of	Classic Hodgkin Lymphoma registry condition “Recurrent Classic Hodgkin Lymphoma” mapped CURATED_BROADER	—	—	Classic Hodgkin Lymphoma	1	Observed	clinicaltrials	graph →
← condition of	Classic Hodgkin Lymphoma registry condition “Refractory Classic Hodgkin Lymphoma” mapped CURATED_BROADER

A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma intervention of …INTERVENTION_OFderived9 of 9
← intervention of	Bendamustinesmall molecule registry intervention “Bendamustine” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Brentuximab Vedotinadc registry intervention “Brentuximab Vedotin” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Carboplatinsmall molecule registry intervention “Carboplatin” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Doxorubicinsmall molecule registry intervention “Pegylated Liposomal Doxorubicin Hydrochloride” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Etoposidesmall molecule registry intervention “Etoposide” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Gemcitabinesmall molecule registry intervention “Gemcitabine” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Ifosfamidesmall molecule registry intervention “Ifosfamide” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Pembrolizumabmonoclonal antibody registry intervention “Pembrolizumab” (BIOLOGICAL) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Vinorelbinesmall molecule registry intervention “Vinorelbine” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →

A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma intervention of …INTERVENTION_OFderived9 of 9

← intervention of

Bendamustinesmall molecule

registry intervention “Bendamustine” (DRUG) mapped ALIAS

—

not mapped

Observed

clinicaltrials

graph →

← intervention of

Brentuximab Vedotinadc

registry intervention “Brentuximab Vedotin” (DRUG) mapped ALIAS

—